Financial Conflicts of Interest Checklist 2010 for clinical research studies

Abstract A conflict of interest is defined as “a set of conditions in which professional judgment concerning a primary interest (such as a patient’s welfare or the validity of research) tends to be unduly influenced by a secondary interest (such as financial gain)” [Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329(8):573–576]. Because financial conflict of interest (fCOI) can occur at different stages of a study, and because it can be difficult for investigators to detect their own bias, particularly retrospectively, we sought to provide funders, journal editors and other stakeholders with a standardized tool that initiates detailed reporting of different aspects of fCOI when the study begins and continues that reporting throughout the study process to publication. We developed a checklist using a 3-phase process of pre-meeting item generation, a stakeholder meeting and post-meeting consolidation. External experts (n = 18), research team members (n = 12) and research staff members (n = 4) rated or reviewed items for some or all of the 7 major iterations. The resulting Financial Conflicts of Interest Checklist 2010 consists of 4 sections covering administrative, study, personal financial, and authorship information, which are divided into 6 modules and contain a total of 15 items and their related sub-items; it also includes a glossary of terms. The modules are designed to be completed by all investigators at different points over the course of the study, and updated information can be appended to the checklist when it is submitted to stakeholder groups for review. We invite comments and suggestions for improvement at http://www.openmedicine.ca/fcoichecklist and ask stakeholder groups to endorse the use of the checklist.

[1]  Robert W. Matthews,et al.  Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication , 2010, Journal of pharmacology & pharmacotherapeutics.

[2]  D. Moher,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. , 2010, Obstetrics and gynecology.

[3]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[4]  D. Moher,et al.  Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.

[5]  Ana Marusic,et al.  Uniform format for disclosure of competing interests in ICMJE journals. , 2010, JAMA.

[6]  Elizabeth Wager,et al.  How to handle authorship disputes: a guide for new researchers , 2009, Science Editor and Publisher.

[7]  J. Ioannidis,et al.  Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.

[8]  B. Williams-Jones,et al.  Conflict of Interest Policies at Canadian Universities: Clarity and Content , 2008 .

[9]  E. Campbell,et al.  Responses of medical schools to institutional conflicts of interest. , 2008, JAMA.

[10]  J. PérezMartín,et al.  [International Committee of Medical Journal Editors]. , 2008, Revista alergia Mexico.

[11]  Ana Marusic,et al.  Clinical trial registration: looking back and moving ahead , 2007, The Lancet.

[12]  J. Kimmelman Inventors as Investigators: The Ethics of Patents in Clinical Trials , 2007, Academic medicine : journal of the Association of American Medical Colleges.

[13]  R. Fletcher Ghost writing initiated by commercial companies , 2005, Journal of General Internal Medicine.

[14]  A. Hrõbjartsson,et al.  Constraints on publication rights in industry-initiated clinical trials. , 2006, JAMA.

[15]  Ermenegyldo Munhoz Junior Requisitos uniformes para manuscritos submetidos a periódicos biomédicos: escrevendo e editando para publicações biomédicas , 2006 .

[16]  R. Steinbrook Gag clauses in clinical-trial agreements. , 2005, The New England journal of medicine.

[17]  David M Studdert,et al.  Academic medical centers' standards for clinical-trial agreements with industry. , 2005, The New England journal of medicine.

[18]  A. Petryna Ethical variability: Drug development and globalizing clinical trials , 2005 .

[19]  G. Loewenstein,et al.  A social science perspective on gifts to physicians from industry. , 2003, JAMA.

[20]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[21]  C. Naylor Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[22]  R. Horton,et al.  Sponsorship, authorship and accountability. , 2001, Lakartidningen.

[23]  R. Horton,et al.  Sponsorship, authorship and accountability. , 2001, The Medical journal of Australia.

[24]  T. Bodenheimer,et al.  Uneasy alliance--clinical investigators and the pharmaceutical industry. , 2000, The New England journal of medicine.

[25]  D Blumenthal,et al.  Looking a gift horse in the mouth: corporate gifts supporting life sciences research. , 1998, JAMA.

[26]  A. Vickers,et al.  Do certain countries produce only positive results? A systematic review of controlled trials. , 1998, Controlled clinical trials.

[27]  D. Rennie,et al.  When authorship fails. A proposal to make contributors accountable. , 1997, JAMA.

[28]  D F Thompson,et al.  Understanding financial conflicts of interest. , 1993, The New England journal of medicine.

[29]  W. Raub From the National Institutes of Health. , 1990, JAMA.

[30]  The National Academy of Sciences , 1928, Science.